Article Text

Download PDFPDF
Severe mitral regurgitation: does one size fit all?
  1. Camille Michael Minder,
  2. Brian K Whisenant
  1. Cardiology, Intermountain Medical Center, Salt Lake City, Utah, USA
  1. Correspondence to Dr Brian K Whisenant, Intermt Heart Inst, Salt Lake City, UT 84107, USA; brian.whisenant{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

For symptomatic patients presenting with chronic severe, primary mitral regurgitation, American College of Cardiology/American Heart Association guidelines recommend surgical mitral valve repair for those with ejection fraction ≥30% or consideration of transcatheter mitral valve repair (TMVR) for those with prohibitive surgical risk.1 2 Contemporary clinical trial evidence also suggests benefit of TMVR for patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remain symptomatic despite optimal medical therapy.3

As such, clinicians are often on the lookout for patients with mitral regurgitation and subjective complaints of dyspnoea, fatigue, palpitations as well as objective findings including decreased exercise capacity, elevated left atrial pressure (LAP), elevated pulmonary pressures, atrial fibrillation and/or the presence of abnormal biomarkers including brain natriuretic peptide to inform clinical decision-making.2 In a young, otherwise healthy patient without multisystem disease and multiple concordant clinical and imaging findings consistent with haemodynamically significant mitral regurgitation, decision-making is generally clear-cut. More often than not, clinicians are faced with a nuanced picture involving an older patient with comorbid disease and/or discordant imaging findings. Whether these patients have symptoms of mitral valve regurgitation or some other physiological derangement may not be readily obvious. To what extent these individuals will benefit from mitral valve intervention to reduce mitral regurgitant volume may be equally challenging using contemporary clinical practice recommendations for guidance.

The challenges inherent to evaluating and treating patients presenting with …

View Full Text


  • Contributors All authors have made substantial contributions to the conception or design of the work, have together drafted and revised for important intellectual content, and provided final approval. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles